EGFR and bladder transitional cell carcinoma: In GBM, TERTp mutations coexist with EGFR amplification [64,77,111], and in urothelial bladder carcinoma, they are associated with FGFR3 (Fibroblast Growth Factor Receptor 3) mutations [61,94].